Goosehead Insurance, Inc. (GSHD), a personal-lines insurance distribution company, is covered by roughly a dozen sell-side firms. The most recent verifiable targets span approximately $42 to $80, with the arithmetic mean landing near $62 after rounding. This wide dispersion reflects a genuine split: several firms still carry Buy or Outperform ratings with targets in the mid-$60s to $80 range, while a larger group of Hold and Neutral ratings cluster in the high-$40s to low-$60s.
The most recent revisions have leaned downward. Piper Sandler downgraded the stock to Neutral and cut its target from $72 to $48 in early October 2026, citing concerns over revenue-growth guidance. Citizens JMP lowered its target from $100 to $80, and Keefe, Bruyette & Woods cut from $72 to $66, while J.P. Morgan trimmed to $60, Truist to $48, BMO Capital to $47, and Bank of America Securities maintained an Underperform/Sell stance at $42. The bull-and-bear split is driven by differing assumptions about how durable the company's premium and commission growth will remain, and whether its valuation can hold up as growth decelerates.
With the stock recently trading near $47.60, reaching a $62 stock price target would require an advance of roughly 30%. That qualifies as a substantial move, not a marginal one. Goosehead's revenue is still growing — consensus estimates point to roughly $425 million in revenue for 2026, up about 16% — but the company has been reinvesting in its franchise and corporate distribution channels, which has pressured near-term margins and earnings. Wall Street currently models EPS (earnings per share) of about $2.10 for 2026, rising toward roughly $2.63 in 2027 as those investments mature. A move toward $62 would likely require the market to regain confidence that revenue growth can hold in the mid-teens while profitability re-accelerates, allowing the stock to command a higher forward multiple than it does today.
Goosehead's core growth engine remains intact. The company continues to add franchise and corporate producers, and its book of policies generates recurring royalty and commission income as premiums renew. Renewal revenue tends to be sticky, which gives the business a degree of visibility that many high-growth financial names lack. If new-producer productivity improves and the elevated investment spending begins to pay off, earnings growth could accelerate into 2027 and justify a higher valuation. Analyst revisions have not been uniformly negative — Cantor Fitzgerald, UBS, and Citizens JMP have retained constructive ratings — and the stock's sharp de-rating in 2026 means even a modest re-rating, combined with higher earnings, could narrow the gap toward $62.
The principal obstacle is the deterioration in sentiment and valuation that defined 2026. The shares have declined sharply from their earlier highs as revenue-growth momentum slowed, and management has guided more cautiously, prompting several firms to trim estimates and targets. A second, widely cited risk is the possibility that generative AI tools disintermediate traditional insurance distribution, pressuring Goosehead's agency-based model. Higher investment spending, softer renewal-commission retention, and margin compression all weigh on near-term EPS, and a stock trading at a forward multiple that already embeds meaningful growth can de-rate quickly if that growth disappoints. If AI-related concerns persist or producer-driven growth stalls, the low-$40s targets imply downside rather than a path to $62.
The stock's steep 2026 decline has left it trading near the lower end of its recent range. The $42-to-$44 area, which corresponds to the lowest analyst targets and recent trading lows, represents the clearest downside support zone, while $50 marks a psychological level the shares have struggled to hold. On the upside, the high-$50s to low-$60s region aligns with the cluster of Hold-rated targets and would likely act as the first meaningful resistance on any recovery toward the $62 level.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply their own assumptions. The next key catalyst is Goosehead's third-quarter earnings report, scheduled for November 9, 2026, where results and forward guidance will test the roughly $0.51 per-share consensus estimate. Beyond that, investors should watch producer-count growth, premium retention and renewal rates, any change to margin guidance, and the pace of analyst estimate revisions. Broader factors, including insurance pricing trends and the market's evolving view of AI disruption risk, will also shape whether the shares can close the roughly 30% gap to $62.
For traders who want a more systematic read on GSHD, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover new opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening allows. Exploring these signals alongside traditional research can add a useful, data-driven layer to the decision-making process.
The $62 central target for Goosehead Insurance reflects the average of a wide and genuinely divided set of analyst views, not a guarantee. Reaching it would require roughly a 30% advance, which appears attainable only if revenue growth holds near current levels and margin pressure from elevated investment spending begins to ease, allowing earnings and valuation to recover together. The bull case rests on recurring renewal revenue and producer expansion; the bear case rests on slowing growth, cautious guidance, and AI-driven disruption risk. With targets spanning $42 to $80 and recent revisions tilting lower, investors should treat $62 as a midpoint scenario to be tested by the upcoming earnings report and subsequent guidance, not as a foregone conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, GSHD has been loosely correlated with BRO. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSHD jumps, then BRO could also see price increases.
| Ticker / NAME | Correlation To GSHD | 1D Price Change % | ||
|---|---|---|---|---|
| GSHD | 100% | -15.64% | ||
| BRO - GSHD | 64% Loosely correlated | +1.25% | ||
| TWFG - GSHD | 60% Loosely correlated | +1.12% | ||
| AJG - GSHD | 59% Loosely correlated | +0.73% | ||
| MRSH - GSHD | 56% Loosely correlated | +1.26% | ||
| AON - GSHD | 52% Loosely correlated | +0.17% | ||
More | ||||
| Ticker / NAME | Correlation To GSHD | 1D Price Change % |
|---|---|---|
| GSHD | 100% | -15.64% |
| GSHD (2 stocks) | 85% Closely correlated | -0.30% |
| Insurance Brokers/Services (22 stocks) | 49% Loosely correlated | +1.45% |